TIGETi003-A

GLD1.3

General

Cell Line

hPSCreg name TIGETi003-A
Cite as:
TIGETi003-A (RRID:CVCL_A5GE)
Alternative name(s)
GLD1.3
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
CTGUi001-A
(FD01, F01)
Donor diseases:
Fabry Disease
UKWNLi007-A
(GLA-515G>A-1, GLA-C172Y-iPSC-1, FD1210/1)
Donor diseases:
Fabry Disease
MDCi009-A
(8993-C11)
Donor diseases:
Leigh Disease
IUFi002-A
Donor diseases:
Leigh syndrome
UAMi001-A
(PCCA23-FiPS4F8)
Donor diseases:
Propionic Acidemia
Last update 5th February 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) (TIGET)

External Databases

BioSamples SAMEA7807679
Cellosaurus CVCL_A5GE
Wikidata Q107117092

General Information

* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
infantile
Synonyms
  • GALC deficiency
  • Galactosylceramidase deficiency
  • Globoid cell leukodystrophy
  • Galactocerebrosidase deficiency
show more synonyms
Is the medical history available upon request? no
Is clinical information available? no

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, XX
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA8152190

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information http://dppm.gaslini.org/biobank
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ospedale San Raffaele Ethical Committe
Approval number TIGET HPCT
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ospedale San Raffaele Ethical Committe
Approval number TIGET HPCT
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Source cell origin
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
Passage number reprogrammed 10

Reprogramming method

Vector type Non-integrating
Vector modified mRNA
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
Medium Other medium:
Base medium: StemMACS iPSC brew
Main protein source:
Serum concentration: %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SOX2
Yes
TRA 1-60
Yes
KLF4
Yes
Score:
Marker Present Absent
mCpG
OCT4
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
SOX17
Yes
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
a-SMA
Yes
CD146
Yes
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
MAP2
Yes
PAX6
Unknown

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Passage number: 16
Karyotyping method: G-Banding

Other Genotyping (Cell Line)